Am J Clin Nutr. 2004 Dec;80(6):1611-7.
Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism.
James SJ,
Cutler P,
Melnyk S,
Jernigan S,
Janak L,
Gaylor DW,
Neubrander JA.
Department of Pediatrics, University of Arkansas for Medical Sciences, and the Arkansas Children’s
Hospital Research Institute, Little Rock, AR 72202, USA. jamesjill@uams.edu
BACKGROUND: Autism is a complex neurodevelopmental disorder that usually presents in early childhood and that is thought to be influenced by genetic and environmental factors. Although abnormal metabolism of methionine and homocysteine has been associated
with other neurologic diseases, these pathways have not been evaluated in persons with autism. OBJECTIVE: The purpose of this study was to evaluate plasma concentrations of metabolites in the methionine transmethylation and transsulfuration pathways in children diagnosed with autism. DESIGN: Plasma concentrations of methionine, S-adenosylmethionine (SAM), S-adenosylhomocysteine
(SAH), adenosine, homocysteine, cystathionine, cysteine, and oxidized and reduced glutathione were measured
in 20 children with autism and in 33 control children. On the basis of the abnormal metabolic profile, a targeted nutritional intervention trial with folinic acid, betaine, and methylcobalamin was initiated in a subset of the autistic children. RESULTS: Relative to the control children, the children with autism had significantly lower baseline plasma concentrations of methionine, SAM, homocysteine, cystathionine, cysteine, and total glutathione and significantly
higher concentrations of SAH, adenosine, and oxidized glutathione. This metabolic profile is consistent with impaired capacity for methylation (significantly lower ratio of SAM to SAH) and increased oxidative stress (significantly lower redox ratio of reduced glutathione to oxidized glutathione) in children with autism. The intervention trial was effective in normalizing the metabolic imbalance in the autistic children. CONCLUSIONS: An increased vulnerability to oxidative stress and a decreased capacity for
methylation may contribute to the development and clinical manifestation of autism.
Abstract
Biol Psychiatry. 1999 Aug 1;46(3):420-4.
Sulphation deficit in “low-functioning” autistic children: a pilot study.
Alberti A,
Pirrone P,
Elia M,
Waring RH,
Romano C.
Department of Pediatrics, Oasi Institute for Research on Mental Retardation and Brain Aging (IRCCS), Troina,
Italy.
BACKGROUND: Parents of autistic children and autism support groups often report that autistic episodes
are exacerbated when the children eat certain foodstuffs such as dairy products, chocolates, wheat, corn sugar, apples, and bananas. The hypothesis that autistic behavior might be related to metabolic dysfunctions has led us to investigate in a group of “low functioning” autistic children and in an age-matched control group each made up of 20 subjects, the sulphation capacity available. METHODS: Utilizing the biochemical characteristics of paracetamol we evaluated by high performance liquid chromatography, the urine paracetamol-sulfate/paracetamol-glucuronide (PS/PG) ratio in all subjects following administration of this drug. RESULTS: The PS/PG ratio in the group of autistic subjects gave a significantly lower results than the control group with p < .00002. CONCLUSIONS:
The inability to effectively metabolize certain compounds
particularly phenolic amines, toxic for the CNS, could exacerbate the wide spectrum of autistic behavior.
Abstract
Biochem J. 2004 Sep 15;382(Pt 3):831-40.
Betaine rescue of an animal model with methylenetetrahydrofolate reductase deficiency.
Schwahn BC,
Laryea MD,
Chen Z,
Melnyk S,
Pogribny I,
Garrow T,
James SJ,
Rozen R.
Department of Pediatrics, Human Genetics and Biology, McGill University-Montreal Children’s Hospital, Montreal, Canada.
MTHFR (methylenetetrahydrofolate reductase) catalyses the synthesis of 5-methyltetrahydrofolate, the folate
derivative utilized in homocysteine remethylation to methionine. A severe deficiency of MTHFR results in hyperhomocysteinaemia and homocystinuria. Betaine supplementation has proven effective in ameliorating the biochemical abnormalities and the clinical course
in patients with this deficiency. Mice with a complete knockout of MTHFR serve as a good animal model for
homocystinuria; early postnatal death of these mice is common, as with some neonates with low residual
MTHFR activity. We attempted to rescue Mthfr-/- mice from postnatal death by betaine supplementation to
their mothers throughout pregnancy and lactation. Betaine decreased the mortality of Mthfr-/- mice
from 83% to 26% and significantly improved somatic development from postnatal day 1, compared with Mthfr-/-
mice from unsupplemented dams. Biochemical evaluations demonstrated higher availability of betaine in suckling
pups, decreased accumulation of homocysteine, and decreased flux through the trans-sulphuration pathway in liver and brain of Mthfr-/- pups from betaine-supplemented
dams. We observed disturbances in proliferation and
differentiation in the cerebellum and hippocampu in the knockout mice; these changes were ameliorated
by betaine supplementation. The dramatic effects of betaine on survival and growth, and the partial reversibility of the biochemical and developmental anomalies in the brains of MTHFR-deficient mice, emphasize an important role for choline and betaine depletion in the pathogenesis of homocystinuria due to MTHFR deficiency.
Abstract
Lancet. 1992 Jan 4;339(8784):25-6.
Abnormal sulphur oxidation in systemic lupus erythematosus.
Gordon C,
Bradley H,
Waring RH,
Emery P.
Department of Rheumatology, University of Birmingham,
UK.
S-carboxy-L-methylcysteine was used to assess the
activity of the S-oxidation pathway of sulphur metabolism
in 35 patients with systemic lupus erythematosus
(SLE); 25 (71%) showed impaired sulphoxidation and
21 (60%) produced virtually no sulphoxides, compared
with 17 (36%) and 2 (4%), respectively, of 47 healthy
controls. The substrate/product ratio of cysteine
oxygenase (plasma cysteine/sulphate) was significantly
higher in SLE patients than in controls (median [interquartile
range] 362 [224-588] vs 65 [44-111]; p less than
0.00001). The alternative pathway of sulphur metabolism,
S-methylation, catalysed by thiolmethyltransferase,
was not impaired in the SLE patients. There is a
biochemical difference in sulphur metabolism between
SLE and rheumatoid arthritis, since both pathways
are impaired in the latter disorder.
Abstract
Toxicol Lett. 2003 Nov 30;145(2):167-74.
Effects of dietary folate intake and folate binding protein-1 (Folbp1) on urinary speciation of sodium arsenate in mice.
Spiegelstein O,
Lu X,
Le XC,
Troen A,
Selhub J,
Melnyk S,
James SJ,
Finnell RH.
Center for Environmental and Genetic Medicine, Institute
of Biosciences and Technology, Texas A&M University
System Health Science Center, 77030, Houston, TX,
USA. ospiegelstein@ibt.tamu.edu
In most mammalian species, arsenic biotransformation
occurs primarily by biomethylation with dimethylarsinic
acid being the predominant metabolite excreted in
the urine. Folbp1 (folate binding protein-1) mediated
intracellular folate uptake is one route by which
cells harvest folate cofactors. In light of the likely
relationship between folate biochemistry and arsenic
biotransformation, our experiments were designed
to test: (1) whether Folbp1 is an important determinant
in arsenic biotransformation, by performing urinary
arsenic speciation in Folbp1 nullizygous (Folbp1(-/-))
and wildtype control mice, and (2) whether dietary
folate deficiency alters arsenic biotransformation
in these mice. Compared to normal folate intake,
folate deficiency caused lower amounts of arsenic
to be excreted in the urine of both the wildtype
controls and Folbp1(-/-) mice. Folbp1(-/-) mice excreted
more dimethylarsinic acid than wildtype control mice
during folate deficiency, but not during normal folate
intake. The present data suggest that inadequate
folate intake may result in decreased biotransformation
and excretion of arsenic, which is likely to increase
arsenic exposure and related toxicities.
Abstract
Am J Clin Nutr. 2004 Dec;80(6):1611-7.
Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children
with autism.
James SJ,
Cutler P,
Melnyk S,
Jernigan S,
Janak L,
Gaylor DW,
Neubrander JA.
Department of Pediatrics, University of Arkansas
for Medical Sciences, and the Arkansas Children’s
Hospital Research Institute, Little Rock, AR 72202,
USA. jamesjill@uams.edu
BACKGROUND: Autism is a complex neurodevelopmental
disorder that usually presents in early childhood
and that is thought to be influenced by genetic and
environmental factors. Although abnormal metabolism
of methionine and homocysteine has been associated
with other neurologic diseases, these pathways have
not been evaluated in persons with autism. OBJECTIVE:
The purpose of this study was to evaluate plasma
concentrations of metabolites in the methionine transmethylation
and transsulfuration pathways in children diagnosed
with autism. DESIGN: Plasma concentrations of methionine,
S-adenosylmethionine (SAM), S-adenosylhomocysteine
(SAH), adenosine, homocysteine, cystathionine, cysteine,
and oxidized and reduced glutathione were measured
in 20 children with autism and in 33 control children.
On the basis of the abnormal metabolic profile, a
targeted nutritional intervention trial with folinic
acid, betaine, and methylcobalamin was initiated
in a subset of the autistic children. RESULTS: Relative
to the control children, the children with autism
had significantly lower baseline plasma concentrations
of methionine, SAM, homocysteine, cystathionine,
cysteine, and total glutathione and significantly
higher concentrations of SAH, adenosine, and oxidized
glutathione. This metabolic profile is consistent
with impaired capacity for methylation (significantly
lower ratio of SAM to SAH) and increased oxidative
stress (significantly lower redox ratio of reduced
glutathione to oxidized glutathione) in children
with autism. The intervention trial was effective
in normalizing the metabolic imbalance in the autistic
children. CONCLUSIONS: An increased vulnerability
to oxidative stress and a decreased capacity for
methylation may contribute to the development and
clinical manifestation of autism.
Abstract
0 Comments